AlphaCrest Capital Management’s Nektar Therapeutics NKTR Stock Holding History

AlphaCrest Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,040	Closed	-$84K	–	1326
2022 Q1	$84K	Sell	1,040 -4,300	-81%	-$636K	﹤0.01%	1219
2021 Q4	$1.08M	Buy	5,340 +3,894	+269%	+$845K	0.04%	751
2021 Q3	$390K	Sell	1,446 -6,695	-82%	-$1.61M	0.02%	1013
2021 Q2	$2.1M	Buy	8,141 +7,373	+960%	+$2.04M	0.09%	350
2021 Q1	$230K	Sell	768 -49	-6%	-$15.3K	0.01%	1098
2020 Q4	$208K	Sell	817 -451	-36%	-$117K	0.02%	1069
2020 Q3	$316K	Buy	+1,268	New	+$399K	0.03%	830
2019 Q4	–	Sell	-980	Closed	-$268K	–	1325
2019 Q3	$268K	Buy	+980	New	+$359K	0.02%	1131

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

AlphaCrest Capital Management's NKTR Position: Q2 2022 in Review

AlphaCrest Capital Management sold out of Nektar Therapeutics (NKTR) in Q2 2022, closing a stake of 1,040 shares — an estimated $84K sold.

AlphaCrest Capital Management first reported a position in NKTR in Q3 2019 and held it in 8 quarters. The position peaked at $2.1M in Q2 2021. 228 funds tracked by Wall St. Rank hold NKTR as of Q2 2022.

AlphaCrest Capital Management reported no remaining Nektar Therapeutics position as of Q2 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 1,040 Nektar Therapeutics shares in Q2 2022, an estimated $84K.
AlphaCrest Capital Management first reported a position in Nektar Therapeutics in Q3 2019 and held it in 8 quarters.
AlphaCrest Capital Management's Nektar Therapeutics position peaked at $2.1M in Q2 2021.
228 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2022.

Based on AlphaCrest Capital Management's 13F filing for Q2 2022, filed 11 Aug 2022.